LeonaBio, Inc. (LONA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

LeonaBio, Inc. (LONA) closed at USD 5.39 on 2026-10-14, a change of +27.4 % over the past year, with a market capitalization of USD 49.84M.

LeonaBio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

LeonaBio, Inc. key figures

Previous close

USD 5.39 (2026-10-14)

1-year change

+27.4 %

Market cap

USD 49.84M

Enterprise value

USD -649,402

P/E ratio (trailing)

-0.23

P/E ratio (forward)

n/a

EPS (trailing)

-23.01

EPS (forward)

n/a

PEG ratio

n/a

Price to book

1.48

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.15

Employees

19

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About LeonaBio, Inc.

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for LeonaBio, Inc. and compare it with other stocks.